AFAguinaldo Figueiredo Freitas

Aguinaldo Figueiredo Freitas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aguinaldo Figueiredo Freitas has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diretriz Brasileira de Insuficiência Cardíaca – 2026

    by Marcus Vinicius Simões, Marcus Vinicius, Lidia Zytynski Moura, Silvia Marinho Martins Alves, Ricardo Mourilhe-Rocha, Luiz Claudio Danzmann, José Albuquerque de Figueiredo Neto, Fabiana Goulart Marcondes-Braga, Mucio Tavares de Oliveira Junior, Denilson Campos de Albuquerque, et al.

    Sumário […] Diretriz Brasileira de Insuficiência Cardíaca – 2026 Sumário […] Diretriz Brasileira de Insuficiência Cardíaca – 2026

  • Prevalence and Clinical Determinants of Optimized Pharmacological Therapy in Heart Failure with Reduced Ejection Fraction

    by Anderson Oliveira Estevan, Ana Luísa Guedes de Franca e Silva, Salvador Rassi, Aguinaldo Figueiredo de Freitas, Salvador Rassi

  • Open Access

    Prevalência e Determinantes Clínicos da Terapia Farmacológica Otimizada na Insuficiência Cardíaca com Fração de Ejeção Reduzida

    by Anderson Oliveira Estevan, Ana Luísa Guedes de Franca e Silva, Salvador Rassi Filho, Aguinaldo Figueiredo de Freitas Júnior, Salvador Rassi

    Fundamento Na insuficiência cardíaca com fração de ejeção reduzida (ICFEr), o tratamento medicamentoso otimizado (TMO) com betabloqueador, inibidores da enzima conversora de angiotensina (IECA), bloqueadores dos receptores de angiotensina II (BRA) (ou sacubitril/valsartana), espironolactona e inibidores do co-transportador de sódio-glicose 2 (iSGLT2) em dose-alvo ou máxima tolerada reduz morbimortalidade. Contudo, dados reais mostram sua subutilização. Objetivo Estimar a prevalência e associações clínicas que interfiram na utilização do TMO na prática clínica. Método Estudo observacional de corte transversal com pacientes ambulatoriais com ICFEr atendidos em hospital terciário. Fatores clínicos associados ao tratamento foram avaliados por regressão logística binária (intervalo de confiança de 95%). Resultados Foram analisados 266 pacientes (idade média de 61 anos; 62,4% do sexo masculino), 113 (42,5%) com etiologia chagásica. Fração de ejeção média foi 34,2%. Vasodilatadores, betabloqueadores, espironolactona e gliflozinas foram prescritos em 88%, 95,9%, 85,3% e 27,4%, respectivamente. A prevalência de TMO foi de 7,9% (21 pacientes). Diabetes foi associado à maior probabilidade de uso da TMO (p=0,034). Doença de Chagas foi associada a menor probabilidade de receber vasodilatadores (p=0,015) e maior uso de furosemida, amiodarona e digoxina (p<0,005). Doença renal crônica (DRC), idade maior que 60 anos, pressão arterial menor que 100mmHg e uso de furosemida foram associados a menor uso de vasodilatadores (p=0,003; 0,025, 0,010 e 0,046). DRC foi associada a menor uso de espironolactona (p=0,002). Diabetes (p=0,002) e uso de furosemida (0,005) foram associadas ao uso de iSGLT2. Conclusão Apesar da prevalência elevada da prescrição de drogas modificadoras de doença, o uso do TMO foi significativamente menor que o esperado. DRC, idade avançada, hipotensão arterial e uso concomitante de furosemida foram associados à redução da probabilidade de receber esses fármacos, enquanto diabetes foi associado com maior chance de uso do TMO.

  • Open Access

    Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial

    by Barry A. Borlaug, Jeffrey M. Testani, Mark C. Petrie, Zhenzhong Wang, Jonathan Cunningham, Kirkwood F. Adams, Offer Amir, Jan Bělohlávek, Edimar Bocchi, Aguinaldo Freitas, et al.

    Relaxin is a peptide hormone that may decrease circulatory congestion and improve kidney function. In this study, we conducted a double-blind, international, multicenter trial to test whether volenrelaxin, a long-acting form of human relaxin, can improve left atrial (LA) function, reduce congestion and improve kidney function in patients with heart failure and preserved ejection fraction (HFpEF). We randomly assigned patients with New York Heart Association (NYHA) class II–IV HFpEF and recent heart failure (HF) decompensation to 25-mg, 50-mg or 100-mg volenrelaxin or placebo administered subcutaneously once weekly. The primary outcome was the change in LA reservoir strain at 26 weeks, with key secondary endpoints including changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP), estimated glomerular filtration rate (eGFR) and safety. The trial was stopped early by the sponsor because of evidence for worsening congestion after 332 participants had been enrolled (mean age 74 years, 49% women, mean body mass index 30.6 kg m − 2 , 31.9% NYHA class III–IV). Compared to placebo, 25-mg volenrelaxin improved LA reservoir strain (+3.9%, 95% confidence interval (CI): 1.1–6.6, P = 0.006) but did not have effects on this outcome at 50-mg (+1.3%, 95% CI: −1.3 to 3.9, P = 0.332) or 100-mg (+0.9%, 95% CI: −1.8 to 3.6, P = 0.521) doses. At 26 weeks, volenrelaxin (pooling all dosages) increased NT-proBNP levels (+24.5%, 95% CI: 2.0–51.8) and had no significant effect on eGFR (+2.2 ml min −1 1.73 m − 2 , 95% CI: −1.8 to 6.3). Volenrelaxin was also associated with a non-significant increase in risk for HF hospitalization compared to placebo (hazard ratio = 2.64, 95% CI: 0.93–7.56, P = 0.070), along with signals for an increased number of cardiovascular and renal serious adverse events (odds ratio = 2.52, 95% CI: 0.95–6.68, P = 0.056). In conclusion, despite some evidence for improvement in LA function at a low dose, treatment with this long-acting form of human relaxin was associated with worsening congestion in patients with recently decompensated HFpEF. ClinicalTrials.gov identifier: NCT05592275 .


  • Open Access

    Megacólon Gigante em Cardiomiopatia Chagásica: Uma Combinação Desafiadora

    by Anderson Oliveira Estevan, Aguinaldo Freitas Jr.

    O presente caso se trata de um homem de 62 anos, portador de cardiomiopatia chagásica, de forma dilatada e arritmogênica, com disfunção ventricular importante e sob terapia de ressincronização cardíaca e cardiodesfibrilador implantável implantados previamente. No segmento ambulatorial anterior à internação, havia registros de arritmias ventriculares recorrentes e múltiplos choques apropriados do dispositivo nos últimos anos. O paciente deu entrada no serviço de emergência com quadro de astenia intensa e dor abdominal, vômitos pós-prandiais e engasgos há uma semana. Estava [...] O presente caso se trata de um homem de 62 anos, portador de cardiomiopatia chagásica, de forma dilatada e arritmogênica, com disfunção ventricular importante e sob terapia de ressincronização cardíaca e cardiodesfibrilador implantável implantados previamente. No segmento ambulatorial anterior à internação, havia registros de arritmias ventriculares recorrentes e múltiplos choques apropriados do dispositivo nos últimos anos. O paciente deu entrada no serviço de emergência com quadro de astenia intensa e dor abdominal, vômitos pós-prandiais e engasgos há uma semana. Estava

  • Open Access

    Giant Megacolon in Chagasic Cardiomyopathy: A Challenging Combination

    by Anderson Oliveira Estevan, Aguinaldo Freitas

    This case concerns a 62-year-old man diagnosed with chagasic cardiomyopathy, presenting with a dilated and arrhythmogenic form, showing significant ventricular dysfunction, and currently undergoing cardiac resynchronization therapy with a previously implanted implantable cardioverter defibrillator. In the outpatient setting prior to admission, the patient’s medical records indicate recurrent ventricular arrhythmias and multiple appropriate shocks from the device over recent years. Upon admission to the emergency department, the patient complained of severe asthenia, abdominal pain, postprandial vomiting, and choking persisting for a [...] This case concerns a 62-year-old man diagnosed with chagasic cardiomyopathy, presenting with a dilated and arrhythmogenic form, showing significant ventricular dysfunction, and currently undergoing cardiac resynchronization therapy with a previously implanted implantable cardioverter defibrillator. In the outpatient setting prior to admission, the patient’s medical records indicate recurrent ventricular arrhythmias and multiple appropriate shocks from the device over recent years. Upon admission to the emergency department, the patient complained of severe asthenia, abdominal pain, postprandial vomiting, and choking persisting for a

  • Open Access

    Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review

    by Antonio da Silva Menezes Junior, Ana Luísa Guedes de França-E-Silva, Henrique Lima de Oliveira, Khissya Beatryz Alves de Lima, Iane de Oliveira Pires Porto, Thays Millena Alves Pedroso, Daniela de Melo e Silva, Aguinaldo F. Freitas

    Hypertrophic cardiomyopathy (HCM) is a heart condition characterized by cellular and metabolic dysfunction, with mitochondrial dysfunction playing a crucial role. Although the direct relationship between genetic mutations and mitochondrial dysfunction remains unclear, targeting mitochondrial dysfunction presents promising opportunities for treatment, as there are currently no effective treatments available for HCM. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews guidelines. Searches were conducted in databases such as PubMed, Embase, and Scopus up to September 2023 using “MESH terms”. Bibliographic references from pertinent articles were also included. Hypertrophic cardiomyopathy (HCM) is influenced by ionic homeostasis, cardiac tissue remodeling, metabolic balance, genetic mutations, reactive oxygen species regulation, and mitochondrial dysfunction. The latter is a common factor regardless of the cause and is linked to intracellular calcium handling, energetic and oxidative stress, and HCM-induced hypertrophy. Hypertrophic cardiomyopathy treatments focus on symptom management and complication prevention. Targeted therapeutic approaches, such as improving mitochondrial bioenergetics, are being explored. This includes coenzyme Q and elamipretide therapies and metabolic strategies like therapeutic ketosis. Understanding the biomolecular, genetic, and mitochondrial mechanisms underlying HCM is crucial for developing new therapeutic modalities.


  • Open Access

    The Importance of Characterizing Chest Pain in the Management of Unstable Angina

    by Daniela Do Carmo Rassi, Aguinaldo Figueiredo Freitas Jr., Salvador Rassi

  • Open Access

    A Importância da Caracterização da Dor Torácica na Conduta em Angina Instável

    by Daniela Do Carmo Rassi, Aguinaldo Figueiredo Freitas Jr., Salvador Rassi

  • Open Access

    Should Combination of Diuretics Always Be Early after the ADVOR and CLOROTIC Trials?

    by Nara Kobbaz, Luana Monferdini, Fernanda Almeida Andrade, Aguinaldo F. Freitas

    There has been remarkable progress in the treatment of heart failure (HF) over the past years. Medications such as angiotensin receptor-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors (SGLT2i), often referred to as the “fantastic four,” have been shown to reduce mortality and hospitalization, in addition to improving patients’ quality of life. The natural history of the disease is characterized by recurrent episodes of decompensation and hospital admission linked to pulmonary and/or systemic congestion. Although diuretics [...] There has been remarkable progress in the treatment of heart failure (HF) over the past years. Medications such as angiotensin receptor-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors (SGLT2i), often referred to as the “fantastic four,” have been shown to reduce mortality and hospitalization, in addition to improving patients’ quality of life. The natural history of the disease is characterized by recurrent episodes of decompensation and hospital admission linked to pulmonary and/or systemic congestion. Although diuretics